816 related articles for article (PubMed ID: 26278687)
1. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Respir Investig; 2019 Jul; 57(4):300-311. PubMed ID: 30853366
[TBL] [Abstract][Full Text] [Related]
3. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
4. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic pulmonary fibrosis: evolving concepts.
Ryu JH; Moua T; Daniels CE; Hartman TE; Yi ES; Utz JP; Limper AH
Mayo Clin Proc; 2014 Aug; 89(8):1130-42. PubMed ID: 24867394
[TBL] [Abstract][Full Text] [Related]
6. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Nakano A; Ohkubo H; Fukumitsu K; Fukuda S; Kanemitsu Y; Takemura M; Maeno K; Ito Y; Oguri T; Niimi A
Intern Med; 2019 Apr; 58(8):1141-1144. PubMed ID: 30568147
[TBL] [Abstract][Full Text] [Related]
7. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.
Enomoto N; Oyama Y; Enomoto Y; Yasui H; Karayama M; Kono M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
Chron Respir Dis; 2019; 16():1479972318809476. PubMed ID: 30380910
[TBL] [Abstract][Full Text] [Related]
8. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
9. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
10. Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis.
Alhamad EH; Masood M; Shaik SA; Arafah M
Clin Respir J; 2008 Oct; 2(4):220-6. PubMed ID: 20298338
[TBL] [Abstract][Full Text] [Related]
11. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
Jo HE; Randhawa S; Corte TJ; Moodley Y
Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
[TBL] [Abstract][Full Text] [Related]
13. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
15. Challenges in IPF diagnosis, current management and future perspectives.
Wells AU; Costabel U; Poletti V; Crestani B; Egan J; Margaritopoulos G; Antoniou K
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Aug; 32 Suppl 1():28-35. PubMed ID: 26237442
[TBL] [Abstract][Full Text] [Related]
16. Right-Angled Traction Bronchiectasis in Differentiating Idiopathic Pulmonary Fibrosis Without Honeycombing From Idiopathic Nonspecific Interstitial Pneumonia.
Kim H; Yoon SH; Lee HJ; Song SG; Koh J; Jeon YK; Chae KJ; Jin GY; Jin KN; Lee KY; Goo JM
Invest Radiol; 2020 Jun; 55(6):387-395. PubMed ID: 32058330
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis: pathogenesis and management.
Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L
Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816
[TBL] [Abstract][Full Text] [Related]
18. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Raghu G; Wells AU; Nicholson AG; Richeldi L; Flaherty KR; Le Maulf F; Stowasser S; Schlenker-Herceg R; Hansell DM
Am J Respir Crit Care Med; 2017 Jan; 195(1):78-85. PubMed ID: 27331880
[TBL] [Abstract][Full Text] [Related]
19. Utility of expiratory thin-section CT for fibrotic interstitial pneumonia.
Tokura S; Okuma T; Akira M; Arai T; Inoue Y; Kitaichi M
Acta Radiol; 2014 Nov; 55(9):1050-5. PubMed ID: 24252818
[TBL] [Abstract][Full Text] [Related]
20. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.
Ryerson CJ; Camp PG; Eves ND; Schaeffer M; Syed N; Dhillon S; Jensen D; Maltais F; O'Donnell DE; Raghavan N; Roman M; Stickland MK; Assayag D; Bourbeau J; Dion G; Fell CD; Hambly N; Johannson KA; Kalluri M; Khalil N; Kolb M; Manganas H; Morán-Mendoza O; Provencher S; Ramesh W; Rolf JD; Wilcox PG; Guenette JA
Ann Am Thorac Soc; 2016 Sep; 13(9):1640-7. PubMed ID: 27348402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
